This decision eliminates a key patent from the Halozyme v. Merck litigation. Monitor the remaining PGR/IPR proceedings on the other 14+ related patents listed in the decision, as well as any Federal Circuit appeal by Halozyme. A sustained win across the patent family would remove a material litigation overhang for Merck's hyaluronidase-related programs.
Price Chart
Executive Summary
The PTAB issued a Final Written Decision in PGR2025-00030, holding all challenged claims (1, 2, and 6–30) of Halozyme's '758 patent unpatentable. The patent covers modified PH20 hyaluronidase polypeptides. Merck Sharp & Dohme LLC (Merck) was the petitioner. The decision removes a patent that Halozyme had asserted against Merck in a pending New Jersey district court case (2:25-cv-03179), reducing Merck's infringement exposure on a patent family central to that litigation.
PTAB Trial Details
Key Facts
- Final Written Decision in PGR2025-00030, issued October 15, 2026.
- All challenged claims (1, 2, and 6–30) of U.S. Patent 12,054,758 B2 held unpatentable.
- Patent owner: Halozyme, Inc. and Halozyme Therapeutics, Inc.
- Petitioner: Merck Sharp & Dohme LLC (Merck & Co., Inc.).
- The '758 patent is part of a broader patent family involved in a pending civil action: Halozyme, Inc. v. Merck Sharp & Dohme LLC, 2:25-cv-03179 (D.N.J.).
- The decision lists 14 other related patents also subject to PGR or IPR proceedings, many also at issue in the same civil action.
Financial Impact
Not stated in the decision. The decision does not quantify damages, revenue at risk, or licensing fees.
Risk Factors
- Halozyme may appeal the decision to the Federal Circuit or seek Director Review.
- Other related patents in the same family remain in active PGR/IPR proceedings and the district court case.
- The decision does not address damages or injunctive relief in the parallel civil action.
Investment Themes
Documents Analyzed
This report is based on 1 PTAB decision.
| Document | Accession Number |
|---|---|
| PTAB-TRIAL Data (Synthetic) | ptab-PGR2025-00030-fwd-MRK |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 3/A | $147.24 | awaiting T+20 | — | $145.27 (−1.34%) |
Oct 21, 2026 5d ago | PTAB Trial | $147.24 | awaiting T+20 | — | $145.27 (−1.34%) |
Oct 15, 2026 11d ago | PTAB Trial | $145.95 | awaiting T+20 | — | $145.27 (−0.47%) |
Oct 15, 2026 11d ago | PTAB Trial | $145.95 | awaiting T+20 | — | $145.27 (−0.47%) |
Oct 13, 2026 12d ago | 8-K | $141.98 | awaiting T+20 | — | $145.27 (+2.32%) |
Sep 29, 2026 27d ago | Court Ruling | $145.31 | awaiting T+20 | — | $145.27 (−0.03%) |
Sep 28, 2026 28d ago | Court Ruling | $149.28 | awaiting T+20 | — | $145.27 (−2.69%) |
Sep 22, 2026 4w ago | Court Ruling | $148.08 $149.88 | ▲ +1.22% | ▲ +0.53% | $145.27 (−1.90%) |
Sep 11, 2026 6w ago | Court Ruling | $144.85 $145.45 | ▲ +0.41% | ▼ −1.85% | $145.27 (+0.29%) |
Sep 9, 2026 6w ago | Court Ruling | $144.71 $142.38 | ▼ −1.61% | ▼ −3.73% | $145.27 (+0.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time PTAB Decision Intelligence
Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers